Division of Alexion Pharmaceuticals Inc.
Latest From Trimeris Inc.
Most HIV/AIDS drugs will be moved from the specialty tier to the generic or non-preferred brand tiers in the individual plans offered by Aetna and its Coventry subsidiary, beginning June 1.
Humana joins Coventry and Cigna in agreeing to lower cost sharing for HIV drugs in health plans offered in Florida.
Cigna agrees to cap cost-sharing for some HIV/AIDS drugs at $200 in its exchange plans in Florida as a result of a consent agreement with state regulators. AIDS activists had filed a complaint with HHS alleging Cigna and three other insurers in the state were discriminating against patients with their high copays for HIV/AIDS drugs.
Last week, personalized cancer vaccine company Dendreon appeared to be in terminal decline as it struggles with low sales of its expensive product for prostate cancer, Provenge (sipuleucel-T), in the face of cheaper, more easily administered and more efficacious competition, and also with a large debt mountain. Dendreon is a rare and, you would think, salutary event in life science investing.
- Therapeutic Areas
- Infectious & Viral Diseases
- North America
- Parent & Subsidiaries
- Alexion Pharmaceuticals Inc.
- Senior Management
Martin A Mattingly, CEO
James R Thomas, CFO
- Contact Info
Phone: (919) 806-4682
2530 Meridian Pkwy., 2nd Fl.
Durham, NC 27713
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.